Please ensure Javascript is enabled for purposes of website accessibility

AstraZeneca's Acquisition of Alexion Is Nearly a Done Deal, But Is It a Good Deal?

By Keith Speights and Brian Orelli, PhD - Jul 17, 2021 at 7:01AM

Key Points

  • AstraZeneca recently received clearance from European Union regulators to acquire Alexion Pharmaceuticals.
  • The deal now only requires an OK from U.K. authorities to close.
  • While Alexion isn't necessarily an exciting acquisition for AstraZeneca, it should provide additional growth for the big drugmaker.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Probably so.

AstraZeneca (AZN 3.08%) hopes to soon close its planned acquisition of Alexion Pharmaceuticals (ALXN). The only hurdle left to jump is obtaining approval from United Kingdom regulators. In this Motley Fool Live video recorded on July 7, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not the Alexion acquisition is a good deal for AstraZeneca.

Keith Speights: AstraZeneca has experienced multiple problems with the launch of its COVID-19 vaccine and we're not going to get into all of those problems but there's more news non-COVID related for AstraZeneca now.

The company's planned acquisition of Alexion seems to be moving along with no issues. The European Commission recently cleared this deal. All AstraZeneca awaits now is a green light in the United Kingdom. It looks like AstraZeneca's acquisition of Alexion is nearly a done deal, but Brian, do you think this is a good deal for the company?

Brian Orelli: I mean, it's not the most exciting acquisition, but it's a good deal nonetheless. On the surface, it looked kind of expensive, they paid a 45% premium at the time for the $39 billion deal, but AstraZeneca said it will be immediately accretive to earnings.

I think that part of that is because they're using some cash, and obviously cash doesn't have a very good return on because interest rates are so low and then they paid some with shares and AstraZeneca shares are actually trading at a higher PE than Alexion's.

I think they're paying with more expensive shares and I think that probably helps the deal valuation. They are also looking for $500 in synergies per year that will max out by the end of the third year.

Alexion has drugs for orphan indications. It has Soliris which has been a blockbuster due to its high price, which is a rare blood disorder because of our PNH, they have a next-generation drug for PNH called Ultomiris, more than half of the patients have switched from Soliris to Ultomiris. That's good because the patents on Soliris are going to run out and then they have some other drugs that will incrementally help AstraZeneca as well.

Brian Orelli, PhD has no position in any of the stocks mentioned. Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$66.64 (3.08%) $1.99
Alexion Pharmaceuticals, Inc. Stock Quote
Alexion Pharmaceuticals, Inc.
ALXN

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
389%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.